MMEDF - Psychedelics the next big thing in treating mental health disorders

U.K.-based COMPASS Pathways' ([[CMPS]] +2.1%) strong U.S. debut (shares up 140% since September 18) is the clearest signal yet that investors are bullish on the prospects of using psychedelics to treat mental health disorders including treatment-resistant depression ((TRD)).Its candidate, COMP360, is a synthetic form of the magic mushroom ingredient psilocybin.Early investors include billionaire Peter Thiel who owns a 7.5% stake. He's not the lone bull on the emerging field. Fellow billionaires Steve Cohen and Bob Parsons as well as Hyatt hotel heir Joby Pritzker have donated funds to the Multidisciplinary Association for Psychedelic Studies ((MAPS)), a nonprofit research and educational organization focused on the prudent legal use of psychedelics and marijuana in medicine.A 216-subject dose-ranging Phase 2 clinical trial in TRD is in process with an estimated primary completion date in May 2021. The primary endpoint is the change from baseline in a depression scale called MADRS at week 12.A "psilocybin" query

For further details see:

Psychedelics the "next big thing" in treating mental health disorders